Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish ...

Most people do not use one drug, but many. SUDs often involve different substances, but the underlying problem is really one ...

Daré Bioscience, Inc. ( DARE) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT [Operator Instructions] We will take our first question from the line of Kemp Dolliver from Brookline Capital Markets.

Immunic, Inc. , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for the first quarter ended March 31, ...

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve ...

Most people do not use one drug, but many. SUDs often involve different substances, but the underlying problem is really one ...

Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...

The Bombay High Court held that reassessment proceedings issued beyond three years for AY 2018-19 were invalid because approval was granted by the Principal Commissioner instead of the competent ...

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic ...

Ridgeline Minerals Corp. is pleased to announce the initiation of the Company's 2026 partner-funded drill program at the Chinchilla Sulfide Carbonate Replacement discovery at the Selena project.